For instance, IMMH002, an orally active S1P1 receptor modulator, desensitized egress of peripheral pathogenic lymphocytes from secondary lymphoid organs and the thymus and significantly relieved psoriasis skin damage in both imiquimod (IMQ, a toll-like receptor 7/8 agonist)-treated mouse models and in guinea pigs with propranolol-induced psoriasis-like skin lesions [23]. Here, TLR7 is linked to psoriasis.